Apollo Hospital Share Price Live Updates: Closing Price Update for Apollo Hospital
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
44 minutes ago
- The Hindu
Science for All: Moondust is less harmful than earth's dust — but don't take a deep breath
(This article forms a part of the Science for All newsletter that takes the jargon out of science and puts the fun in! Subscribe now!) You wake up, brush, shower, dress up, grab breakfast, put on your shoes, and step out. It's a new morning and the sun is up, so you take a deep breath — and the city air serves you a gross reminder of why it's become a terrible idea to take deep breaths. Suddenly you're coughing, tearing up, and sneezing. Your nose rapidly becomes blocked. This is perhaps the least of what city dust does to the human body. The particulate matter smaller than 2.5 micrometres, or PM2.5, in particular has been linked to a variety of medical conditions, including those affecting newborns and reducing human lifespan. Unfortunately for you, even if you move to a moon base in future, you'd be ill-advised to take a deep breath of your cabin's air if it has moondust suspended in it. According to a study published recently in Life Sciences in Space Research, moondust is less harmful than the particulate matter we frequently encounter on the earth. However, both our urban dust and moondust seem capable of damaging certain lung cells. The study's authors, from institutes in Macquarie Park, Sydney, and Ultimo in Australia, used two laboratory-generated versions of lunar dust — called LMS-1 and LHS-1, mimicking dust from the moon's mare and highland regions, respectively — in their experiments. During NASA's Apollo missions from 1969 to 1972, astronauts complained of lunar dust sticking to their spacesuits and irritating their eyes and lungs. Lunar dust is statically charged, so it tends to stick to surfaces the same way a balloon rubbed against hair will cling to a wall right after. The researchers used two groups of cells to represent the bronchial and the alveolar parts of human lungs. The bronchi transport air into the lungs while the alveoli are the sacs where the air exchanges oxygen with the blood. The researchers found that large particles from both LMS-1 and LHS-1 moondust were toxic and inflammatory only at extremely high concentrations. The smaller particles in both dust types that a human could breathe deep into the lungs were found to be less toxic to bronchial cells than PM2.5 particles on the earth are known to be. This said, both the moondust simulants and earth dust caused alveolar cells to die. The study is important because space agencies like NASA in the U.S. and CNSA in China are planning to send astronauts to the moon. NASA's Artemis II mission is currently scheduled for 2026 and will carry four astronauts in a lunar flyby mission as an early step to 'long-term return' to the natural satellite. In future, as the human population on the moon builds up, both engineers designing and operating lunar habitats and medical workers expected to attend to the people inhabiting them will gain by understanding how moondust affects the human body. From the Science pages Question Corner How does the material of a string affect an instrument's sound? Find out here Flora and fauna
Time of India
4 hours ago
- Time of India
Apollo Hospital Share Price Live Updates: Solid monthly returns for Apollo Hospital
03 Jul 2025 | 09:06:08 AM IST Welcome to the Apollo Hospital Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ahead of the market with our in-depth coverage of Apollo Hospital, including: Last traded price 7457.0, Market capitalization: 106990.16, Volume: 1000, Price-to-earnings ratio 74.0, Earnings per share 100.56. Get a complete picture of Apollo Hospital's performance through our comprehensive blend of fundamental and technical indicators. Stay informed about breaking news that can influence the stock's trajectory. Our liveblog equips you with the knowledge and insights needed to make confident investment decisions. Don't miss out on the latest updates as Apollo Hospital continues to make waves in the market. The data points are updated as on 09:06:07 AM IST, 03 Jul 2025 Show more
Mint
20 hours ago
- Mint
Apollo Hospitals: Simplifying corporate structure could lead to rerating
Apollo Hospitals Enterprise Ltd has decided to give its existing shareholders direct ownership of its subsidiary, Apollo Healthco Ltd. Apollo Healthco will have online, offline, retail, and wholesale pharmacy segments under one umbrella, apart from the digital consultation and treatment business of Apollo 24|7. The new entity will have nearly 667 million equity shares with a face value of ₹2 each. Apollo Hospitals' shareholders will receive 195.2 shares of Apollo Healthco for every 100 shares they hold. Apollo Healthco's listing is likely in 18-21 months. The exercise would mean that Apollo Hospitals would only have a 17.5% stake (direct plus indirect through its other subsidiaries) in Apollo Healthco, as against the earlier plan of having a 59.2% stake. Also Read: Will Torrent Pharma's big bet on JB Chemicals pay off? The two separate listed entities with dedicated leadership will allow the management teams to sharpen their focus on hospital and pharmacy businesses separately. Following the announcement, Apollo Hospitals shares touched a new 52-week high of ₹7,584.50 apiece on Tuesday. Growth potential Is there more steam left based on the separate valuation of the two businesses? Well, the answer depends on the management's ability to achieve the aspirational targets for its pharmacy business—Apollo Healthco. According to the company's presentation, Apollo Healthco's FY25 revenue (pro forma without the restructuring) was ₹16,377 crore. The management aspires for an operating revenue of ₹25,000 crore in FY27, which would mean a compound annual growth rate of 24% over the two years from FY25. This would require a significant pick-up in growth, given that the FY25 revenue had increased 19% year-on-year. Excluding Apollo 24|7 losses, the FY25 Ebitda margin was already about 6%. So, the Ebitda margin target of 7% in FY27 with operational efficiencies is achievable as it would only require Apollo 24|7 to achieve breakeven. If management is able to deliver on the aspirational numbers, it would mean an Ebitda of ₹1,750 crore in FY27. Based on the EV/ Ebitda multiple of 30x assigned by analysts at Nomura, the market capitalization attributable to Healthco is about ₹50,000 crore, as the net debt is small. Ebitda stands for earnings before interest, taxes, depreciation, and amortization. Also Read: Tech Mahindra: What can upset its apple cart Apollo Hospitals' market capitalization is now ₹1.08 trillion. So, the residual market capitalization of Apollo Hospitals, after deducting the valuation of Apollo Healthco is at ₹58,000 crore. With a net debt of around ₹5,000 crore, the implied EV/Ebitda valuation multiple of Apollo Hospitals comes to 20x based on Nomura's estimate of ₹3,150 crore Ebitda for FY26 (Apollo Health and Lifestyle having sugar clinic, dental clinic, etc. not considered due to its small size). Nomura's fair value multiple for Apollo Hospitals at 25x is higher than the derived implied multiple at 20x, implying room for upside. The growth prospects of standalone Apollo Hospitals are strong. Its future growth is likely to be largely led by capacity additions, unlike the last three years to FY25, when it relied on average revenue per occupied bed (Arpob) for growth. Apollo Hospitals had 8,025 operating beds at FY25 end. This is likely to rise by more than 50% as it plans to add nearly 4,400 beds over the next 3-4 years to address supply-side constraints, even though getting more patients is also crucial. The management expects to maintain the Ebitda margin of the hospital business at 24% even after the large expansion. Also Read: Nykaa's premium bet: A smart strategy if it delivers The hospital business has a higher Ebitda margin but is more capital-intensive in nature, whereas the pharmacy business has a lower Ebitda margin but lower capital requirements. Besides, the separate listing of Apollo Healthco would mean that the shareholders of Apollo Hospitals would have an option to choose the business they want to remain invested in.
